NEWARK, Delaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc. Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.
“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary H³ antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”
Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®. Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.
BIOSION ALL RIGHTS RESERVED.
NEWARK, Delaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc. Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.
“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary H³ antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”
Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®. Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.
BIOSION ALL RIGHTS RESERVED.